By integrating molecular diagnostics with histopathological subtyping of meningiomas, the updated criteria introduced several genetic and epigenetic alterations associated with a higher risk of recurrence and worse prognosis, including TERT promoter mutations [38], homozygous deletion of CDKN2A/B [39], H3K27me3 loss of nuclear expression [40], and a hypermitotic DNA methylation profile [41]. The gene discussed is CDKN2A; the disease is meningioma.